| COVID-19 |
1 |
1 |
| Type 2 Diabetes Mellitus |
0 |
0.9 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.89 |
| Antiviral Agents |
0 |
0.27 |
| Electronic Medical Record |
0 |
0.27 |
| Electronic Health Record (EHR) |
0 |
0.24 |
| Healthcare and Medical Technology |
0 |
0.16 |
| Obesity |
0 |
0.16 |
| Prediabetes |
0 |
0.16 |
| Allergy |
0 |
0.09 |
| Bioinformatics |
0 |
0.09 |
| Clinical Research |
0 |
0.09 |
| Food and Drug Administration (FDA) |
0 |
0.09 |
| Microbiology |
0 |
0.09 |
| Minnesota |
0 |
0.09 |
| Translational Research |
0 |
0.09 |
| Viral Load |
0 |
0.09 |
| Microbiome |
0 |
0.08 |